Padmasini Kumar
Publications by Year
Research Areas
Immunotherapy and Immune Responses, RNA Interference and Gene Delivery, Cancer Research and Treatments, S100 Proteins and Annexins, Cancer Immunotherapy and Biomarkers
Most-Cited Works
- → Lipopolysaccharides from Distinct Pathogens Induce Different Classes of Immune Responses In Vivo(2001)475 cited
- → Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer(2006)359 cited
- → Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer(2011)193 cited
- → Phase II trial of Belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients(2009)146 cited
- → Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer(2016)88 cited
- → CAP37, a Novel Inflammatory Mediator(2002)60 cited
- → CAP37, a neutrophil-derived inflammatory mediator, augments leukocyte adhesion to endothelial monolayers(2003)57 cited
- → Expression of CAP37, a novel inflammatory mediator, in Alzheimer's disease(1996)57 cited
- → Phase I Trial of TGF-β2 Antisense GM-CSF Gene-Modified Autologous Tumor Cell (TAG) Vaccine(2011)54 cited
- → Pilot Trial of FANG Immunotherapy in Ewing's Sarcoma(2015)53 cited